A registry study called the “Pulmonary Fibrosis Contract Registry” is being conducted by the Pulmonary Fibrosis Foundation in collaboration with the Patient Centered Outcome Research Institute (ClinicalTrials.gov Identifier: NCT01935726) This is an observational prospective study that will run for 20 years with the goal of…
A phase III clinical trial sponsored by the Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (FISEVI) in Spain is currently recruiting participants to enroll in a study designed to assess the efficacy of idiopathic pulmonary fibrosis (IPF) treatment, cotrimoxazole (TriSulfa-FPI). The study is entitled “…
A recent report on Research and Markets covered this year’s featured companies’ Pipeline Therapeutics for the annual Pulmonary Fibrosis Review. The report details descriptions of 56 companies currently developing treatment strategies for therapeutics for Pulmonary Fibrosis. The team conducted comparative analysis of the companies’ compounds under clinical investigation at various stages, and…
A new study published in the March 3 issue of the Journal of the American Medical Association (JAMA) finds that a medical need-based donor lung allocation protocol has been associated with better graft survival than single-lung transplantation procedures in persons afflicted with idiopathic pulmonary fibrosis (IPF). The…
(Back row, left to right) Broadway Belts for PFF! cast members, Julia Murney, Randy Graff, Julie Halston, Erich Bergen, Zakiya Young, Betsy Wolfe (Front row, left to right) Bobby Creighton, Annaleigh Ashford, Santino Fontana. The Tony award-winning cast performed at the Broadway Belts for PFF! fundraiser to…
Dr. Thomas Kuerner at Nippon Boehringer Ingelheim Co., Ltd. in Japan published a review regarding the critical rules and requirements for global clinical trials in rare lung diseases such as pulmonary fibrosis from a sponsor’s perspective. The review was published in the journal…
Researchers from Shanghai Jiao Tong University in China published in the journal BioMed Research International their findings on the mechanism behind acute lung injury and pulmonary fibrosis observed after poisoning with the chemical paraquat. The study is entitled “DNaseI Protects…
Galapagos NV recently announced that GLPG1690, its molecule to address pulmonary diseases such as pulmonary fibrosis, has demonstrated target engagement and a very good safety profile, with Phase 1 results showing favorable drug properties. Galapagos is now advancing GLPG1690 with partner Janssen Pharmaceutica NV. Pulmonary fibrosis…
Results from a recent survey called EXPLORE IPF showed that people with idiopathic pulmonary fibrosis (IPF) have a lack of understanding of their disease, experience significant emotional difficulties, and report the need for more support and care resources to help them deal with their condition. “These survey findings remind me of…
Researchers from the Nippon Medical School in Tokyo published a report in the journal Respiratory Medicine Case Reports highlighting an individual case study of a patient with pulmonary hypertension associated with idiopathic pulmonary fibrosis that had a good overall improvement after treatment with bosentan. The prevalence…
Get regular updates to your inbox.
